ETFs positioned on Novo Nordisk A/S

Name Weight AuM 1st Jan change Investor Rating
21.31% 209 M€ +2.02%
10.45% 4 M€ +3.33%
5.40% 30 M€ +1.14% -
3.95% 0 M€ -.--% -
3.91% 0 M€ +5.66% -
3.91% 0 M€ +10.09% -
3.78% 0 M€ -.--%
3.41% 0 M€ -.--% -
3.09% 0 M€ +15.09% -
2.87% 0 M€ +8.37% -
2.53% 0 M€ -.--%
2.22% 0 M€ +11.67% -
1.91% 0 M€ +9.19% -
1.91% 0 M€ -.--% -
1.67% 0 M€ -3.35% -
1.60% 0 M€ +6.14% -
1.31% 0 M€ +11.32%
1.04% 0 M€ +11.40% -
1.03% 8 M€ +1.46% -
1.02% 33,076 M€ +1.56% -
0.89% 1,017 M€ +0.63%
0.79% 0 M€ -.--%
0.76% 0 M€ -.--% -
0.75% 0 M€ -.--%
0.70% 0 M€ +0.11% -
0.64% 0 M€ +15.64% -
0.64% 0 M€ +14.54% -
0.64% 0 M€ -.--%
0.57% 808 M€ +3.23%
0.56% 0 M€ -.--% -
0.56% 0 M€ -.--%
Logo Novo Nordisk A/S
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Employees
71,880
Calendar
More about the company
Trading Rating
Investor Rating
ESG MSCI
AAA
surperformance-ratings-light-chart NOVO-NORDISK-A-SMore Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
551.30DKK
Average target price
830.68DKK
Spread / Average Target
+50.68%
Consensus

Quarterly revenue - Rate of surprise